URAPIDIL ZENTIVA LP 30 mg, extended-release capsule 30 capsules, CIP 3400930201862
Active ingredients: Urapidil
Commercialized according to BDPMDispensing in France: Prescription only
Extended-release capsule30 capsules, CIP 3400930201862orale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- URAPIDIL ZENTIVA LP 30 mg, gélule à libération prolongée
- Pharmaceutical form
- gélule à libération prolongée
- Route of administration
- orale
- Presentation description
- 1 flacon(s) polyéthylène haute densité (PEHD) dessicant de 30 gélule(s)
- Marketing authorisation holder
- ZENTIVA FRANCE
- Reimbursement according to BDPM
- 65 %
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 25 May 2025
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
60652523CIP73020186CIP133400930201862Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| URAPIDILgélule | 30 mg · une gélule | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Other packages of this medicine
The same medicine in another pack size, according to BDPM.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.